Press release
Oropharyngeal Cancer Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others
Oropharyngeal Cancer Pipeline
In the Oropharyngeal Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Oropharyngeal Cancer NDA approvals (if any), and product development activities comprising the technology, Oropharyngeal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Oropharyngeal Cancer pipeline treatment landscape of the report, click here @ Oropharyngeal Cancer Pipeline Outlook- https://www.delveinsight.com/report-store/oropharyngeal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Oropharyngeal Cancer Pipeline Report
• DelveInsight's Oropharyngeal Cancer Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading Oropharyngeal Cancer Companies working in the market include AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others.
• Promising Oropharyngeal Cancer Pipeline Therapies in the various stages of development include ISA101b, Cisplatin, Cemiplimab, Durvalumab, HB-201 IV, Nivolumab Injection, GC4419, APG-157, Pembrolizumab, and others.
• On April 2023, ISA Pharmaceuticals announced a study of phase 2 clinical trials for ISA101b. This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
• On April 2023, Fox Chase Cancer Center announced a study of phase 2 clinical trials for Cisplatin. This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
• On July 2023, Hookipa Biotech GmbH announced a study of early phase 1 clinical trials for HB-201 IV. This Window of Opportunity clinical trial will examine the immunologic effects of the study agent HB-201 in the head and neck or cervical cancer, when administered by IV route.
• On July 2023, Robert Ferris announced a study of phase 2 clinical trials for Nivolumab Injection. This clinical trial will evaluate a new combination of treatments for Oropharyngeal Squamous Cell cancers (OPSCC), and compare it to the current standard of care (concurrent, platinum-based chemoradiotherapy). Chemoradiotherapy is efficacious, but also associated with significant toxicities and is only suitable for patients with good performance status and without severe comorbidities. The purpose of this trial is to demonstrate equivalent oncologic outcome with fewer adverse effects and improved quality of life when compared to the standard of care.
Oropharyngeal Cancer Overview
Oropharyngeal Cancer is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat.
To explore more information on the latest breakthroughs in the Oropharyngeal Cancer Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Oropharyngeal Cancer Emerging Drugs Profile
• Cisplatin: AstraZeneca
• ISA101B: ISA Pharmaceuticals
Oropharyngeal Cancer Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Oropharyngeal Cancer. The Oropharyngeal Cancer companies which have their Oropharyngeal Cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.
Request a sample and discover the recent advances in Oropharyngeal Cancer Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Oropharyngeal Cancer Drugs and Companies
• ISA101b: ISA Pharmaceuticals
• Cemiplimab: Regeneron Pharmaceuticals
• Cisplatin: University of Birmingham
• Durvalumab: AstraZeneca
• HB-201 IV: Hookipa Biotech GmbH
Oropharyngeal Cancer Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Oropharyngeal Cancer Therapeutics Market include-
AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others.
Dive deep into rich insights for drugs for Oropharyngeal Cancer Pipeline, click here for Oropharyngeal Cancer Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Oropharyngeal Cancer Pipeline Report
• Coverage- Global
• Oropharyngeal Cancer Companies- AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others.
• Oropharyngeal Cancer Pipeline Therapies- ISA101b, Cisplatin, Cemiplimab, Durvalumab, HB-201 IV, Nivolumab Injection, GC4419, APG-157, Pembrolizumab, and others
• Oropharyngeal Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Oropharyngeal Cancer Mergers and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/oropharyngeal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Oropharyngeal Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Oropharyngeal Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Oropharyngeal Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Cisplatin: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. ISA101B: ISA Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I/II)
16. Genakumab: GeneScience Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Oropharyngeal Cancer Key Companies
20. Oropharyngeal Cancer Key Products
21. Oropharyngeal Cancer- Unmet Needs
22. Oropharyngeal Cancer- Market Drivers and Barriers
23. Oropharyngeal Cancer- Future Perspectives and Conclusion
24. Oropharyngeal Cancer Analyst Views
25. Oropharyngeal Cancer Key Companies
26. Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oropharyngeal Cancer Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | AstraZeneca, ISA Pharmaceuticals, Pfizer, Bristol Myers Squibb, Advaxis, PDS Biotechnology, Debiopharm, Merck KGaA, Regeneron Pharmaceuticals/Sanofi, and others here
News-ID: 3136795 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Oropharyngeal
Oropharyngeal Cancer Market growing at a CAGR of around 6.4%
Oropharyngeal Cancer Market Overview
The Oropharyngeal Cancer Market was valued at ~USD 2.9 billion in 2024 and is projected to reach ~USD 5.4 billion by 2034, growing at a CAGR of around 6.4%. Growth is driven by rising HPV-associated cancers, improved screening tools, and expanding adoption of immunotherapy and targeted oncology treatments.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71260
Key Market Drivers
• Increasing global prevalence of HPV-positive oropharyngeal cancers.
• Growing use of…
Oropharyngeal Cancer Market
Introduction
Oropharyngeal cancer (OPC) is a type of head and neck cancer that develops in the oropharynx, the part of the throat located at the back of the mouth. This cancer affects areas such as the tonsils, base of the tongue, and the soft palate, and it is closely linked to the human papillomavirus (HPV) infection. OPC is becoming an increasingly significant health concern, especially in regions like North America and…
Oropharyngeal Cancer Market Future Business Opportunities 2025-2032 |Innate Phar …
Latest Report, titled "Oropharyngeal Cancer Market" Trends, Share, Size, Growth, Opportunity and Forecast 2025-2032, by CoherentMI offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The oropharyngeal cancer market is estimated to be valued at USD 2.11 Bn in 2024 and is expected to reach USD 3.05 Bn by 2031, growing at…
Oropharyngeal Airway Market Size 2024 to 2031.
Market Overview and Report Coverage
An oropharyngeal airway is a medical device used to maintain an open airway in unconscious patients. The device is placed in the mouth to prevent the tongue from obstructing the airway and ensure proper ventilation. The global oropharyngeal airway market is expected to grow at a CAGR of 11.90% during the forecasted period.
The increasing prevalence of respiratory diseases, emergency medical situations, and surgical procedures…
Human Papillomavirus-positive Oropharyngeal Cancer Market to Witness Growth by 2 …
DelveInsight's "Human Papillomavirus-positive Oropharyngeal Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Human Papillomavirus-positive Oropharyngeal Cancer, historical and forecasted epidemiology as well as the Human Papillomavirus-positive Oropharyngeal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Human Papillomavirus-positive Oropharyngeal Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies,…
Oropharyngeal Airway Market 2021 Growth, COVID Impact, Trends Analysis Report 20 …
Oropharyngeal Airway Market is thoroughly, accurate and comprehensively assessed in a report focusing on market dynamics, market competition, regional growth, segment analysis, and key growth strategies. Report buyers will have access to proven market figures including global market size in terms of revenue and volume.
(Get 15% Discount on Buying this Report)
A full report of Global Oropharyngeal Airway Market is available at: https://www.orionmarketreports.com/oropharyngeal-airway-market/57268/
The Oropharyngeal Airway key manufacturers in this market include:
• Well…
